iCo Therapeutics Inc. (TSXV:ICO), a biotech stock, moved up after announcing that it has dosed the first patient in its Phase 1 clinical study for Oral Amphotericin B
A dose of good news yielded a healthy return for a Canadian biotech stock Wednesday. Here’s some small stocks making big moves on Wednesday, April 18, 2018 (as of 4 pm EST):
iCo Therapeutics Inc. (TSXV:ICO), a biotech stock, gained 33% to $0.04 on Wednesday after announcing that it has dosed the first patient in its Phase 1 clinical study for Oral Amphotericin B for treatment of fungal and parasitic infections. The Company added that it remains on track to complete dosing of patients in the Phase 1 study by the end of Q2 2018.
As well, shares of Energold Drilling Corp. (TSXV:EGD) slid 22% to $0.375 as the specialty drilling company said some excess rig capacity in the industry in 2017 impacted pricing, which weighed on the Company’s 2017 financial results.
Painted Pony Energy Ltd. (TSX:PONY), meanwhile, reported that the discovery test results for the first Montney horizontal well drilled on the Beg block averaged an estimated rate over 2,000 boe/d including 10 MMcf/d of natural gas and an estimated 360 bbls/d of liquids. Painted Pony Energy stock moved up 5% to $2.29 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
iCo Therapeutics Inc. (TSXV:ICO), a biotech stock, gained 33% to $0.04 on Wednesday after announcing that it has dosed the first patient in its Phase 1 clinical study for Oral Amphotericin B for treatment of fungal and parasitic infections. The Company added that it remains on track to complete dosing of patients in the Phase 1 study by the end of Q2 2018.
